Current guidelines recommend a cyclin-dependent kinase (CDK) 4/6 inhibitor in combination with endocrine therapy (ET) as the first-line treatment for hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) ABC, the most common subtype of ABC [3–5]. Here, NR4A1 is linked to aneurysmal bone cyst.